Abstract It has been known for a long time that changes in cardiac function are a major component of the clinical presentation of thyroid disease. Increased heart rate and hyperdynamic circulation are hallmarks of hyperthyroidism, while bradycardia and decreased contractility characterize hypothyroidism. Recent findings have provided novel insights in the physiology and pathophysiology of heart regulation by thyroid hormones. In this review, we summarize the present knowledge on thyroxine (T 4 ) transport and metabolism and on the biochemical pathways leading to genomic and non-genomic effects produced by 3,5,3 0 -triiodothyronine (T 3 ) and by its active metabolites, particularly 3,5-diiodothyronine (T 2 ) and 3-iodothyronamine (T 1 AM). On this basis, specific issues of special interest for cardiology are discussed, namely (1) relevance of the regulation of proteins involved in the control of calcium homeostasis and in pacemaker cell activity, due to non-genomic as well as to classical genomic effects; (2) stimulation of fatty acid oxidation by T 2 and T 1 AM, the latter also causing a negative inotropic and chronotropic action at micromolar concentrations; (3) induction of D3 deiodinase in heart failure, potentially causing selective cardiac hypothyroidism, whose clinical implications are still controversial; and (4) cardioprotective effect of T 1 AM, possibly occurring at physiological concentrations, and relevance of T 3 and of thyroid hormone receptor a 1 in postinfarction repair.
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Introduction
The heart is a major target of thyroid hormone (TH), and cardiac symptoms are important components of the clinical picture of hypo-and hyperthyroidism. Experimental and clinical endocrinology has long relied on two assumptions: (1) TH acts by interacting with nuclear TH receptors (TRs), modulating the expression of a wide range of target genes; and (2) TH availability can be evaluated by assaying serum 3,5,3 0 -triiodothyronine (T 3 ) that has the highest affinity for TRs, and its precursor thyroxine (T 4 ) that has a lower affinity for TR and is regarded as a pro-hormone. The term ''thyroid hormones'' (THs) is often used to refer to both T 3 and T 4 .
These assumptions turned out to be simplistic. It has been ascertained that many effects of TH do not involve the modulation of gene expression [1] . On the other hand, evidence has been provided, suggesting that cellular TH concentration is not directly related to serum T 3 and T 4 , because of the complexity of their transmembrane transport and tissue metabolism [2, 3] . In addition, putative TH metabolites, namely 3,5-diiodothyronine (T 2 ) and 3-iodothyronamine (T 1 AM) have been shown to be independent chemical messengers, whose effects may be different from those produced by TH [4] [5] [6] [7] .
In this review, we will summarize some consequences of this paradigm shift. In particular, we will discuss cardiac TH transport and metabolism, the putative production of active metabolites, cardiac genomic and non-genomic responses to TH and TH-related messengers, and the potential pathophysiological implications of the novel acquisitions.
Thyroid hormone distribution and metabolism in heart
Membrane transport THs have to cross the plasma membrane to reach their receptors. Since THs have a lipophilic skeleton, it was initially believed that their passage through the cell membrane occurred by passive diffusion [8, 9] . In 1954, Christensen et al. [10] first suggested the presence of energy-dependent mechanisms for the entry of THs in the intracellular space. Subsequent investigations addressed the possibility of a plasma membrane transport, and the existence of a saturable and stereospecific TH uptake was eventually demonstrated [11] [12] [13] [14] . However, only recently TH transporters have been identified at the molecular level, and their importance has been highlighted by the identification of a neurological syndrome, Allan-Herndon-Dudley syndrome, characterized by severe neurological involvement and reduced cerebrospinal fluid (CSF) T 4 concentration [15] , which is associated with genetic mutation of a specific TH transporter.
TH transporters belong to the solute carrier gene (SLC) gene family and include members of the following groups: monocarboxylate transporters (MCT), Na ? /taurocholatecotransporting polypeptide (NTCP), large neutral amino acid transporters (LAT) and organic anion-transporting polypeptide (OATP) family [12] [13] [14] [16] [17] [18] [19] . Apart from MCT8, all transporters are also involved in the translocation of other substances, mainly steroids and amino acids, whose tissue concentrations exceed by far TH concentrations.
Monocarboxylate transporters involved in THs entry in the intracellular space are MCT8 (encoded by SLCA16A2 gene) and MCT10 (encoded by SLCA16A10 gene). They belong to a family of proteins with 12 transmembrane domains and act in a sodium-and proton-independent fashion [18] . MCT8 is involved in the transport of T 4 , T 3 but also of 3,3 0 ,5 0 -triiodothyronine (rT 3 ) and 3,5-diiodothyronine (T 2 ) [19] . In humans, MCT8 mutations are responsible for the Allan-Herndon-Dudley syndrome. MCT10 is also a transporter for aromatic acids. When compared to MCT8, it has lower affinity for T 4 and slightly higher affinity for T 3 [20] .
NTCPs are glycoproteins with seven transmembrane domains that belong to the solute carrier gene family 10A (SCL101) [21] . They are involved in the enterohepatic circulation of bile acids and transport the sulfate derivatives of T 4 and T 3 [22] .
LAT are heterodimeric proteins formed by a 12-transmembrane-domain light chain and a glycosylated heavy chain with one transmembrane domain [23, 24] . They carry neutral amino acids inside the cell. LAT1 (encoded by SLC7A5) and LAT2 (encoded by SLC7A8) are involved in the transport of THs, and LAT1 has a higher affinity than LAT2 for T 3 [25] .
OATPs are 12-transmembrane-domain proteins, involved in transport of amphipathic organic compounds such as steroids, bile salts, drugs and anionic oligopeptides [26] . Oatp1c1, Oatp1a4, Oatp3a1 and Oatp2b1 are able to transport THs. All of them transport T 4 [27-30], Oatp1a4 also transports T 3 [22, 30] , and Oatp1c1 transports T 4 , T 3 , rT 3 and T 4 sulfate [22] .
With regard to cardiomyocytes, most investigations have focused on mRNA or protein expression of specific TH transporters. As for other tissues, early studies in 1996 and 2001 confirmed that cardiomyocytes show energy-and Na ? -dependent carriers for both T 4 and T 3 [11, 31, 32] , and the main classes of TH transporters turned out to be OATPs and MCTs.
MCT8 is prominently expressed in the heart, while MCT10 is expressed only at low levels [33] . With regard to OATPs, the prevailing subtypes are OATP2B1 [34], OATP2A1 and OATP4A1 [35] .
At the present stage, the lack of comprehensive functional studies does not permit to build a complete and thorough picture of the mechanisms of TH transport inside cardiomyocytes and to understand the specific role of the different classes of transporters expressed at the cardiac level.
Metabolism
Once inside the cell, TH undergo tissue-specific metabolism that includes deiodination, sulfonation, conjugation, deamination and decarboxylation. Cardiac metabolism consists of deiodination, which is discussed below, and possibly decarboxylation and deamination, which are discussed in the following paragraphs.
Deiodinases are the major enzymes involved in the regulation of TH tissue availability [36, 37], since they modulate T 3 concentration removing specific iodine atoms from T 4 . Deiodination of the phenolic ring (5 0 -deiodination or outer ring deiodination), causes T 4 activation into T 3 , whereas deiodination at the level of the tyrosyl ring (5-deiodination or inner ring deiodination) inactivates T 4 yielding 3,3 0 ,5 0 -triiodothyronine, also known as reverse T 3 (rT 3 ) [38] .
Three types of deiodinases have been identified and named type I (D1), II (D2) and III (D3) deiodinase. They include a selenocysteine residue at the catalytic domain and have different specificity. Indeed, D1 can function as either an outer or inner ring iodothyronine deiodinase; D2 only acts as an outer ring deiodinase, whereas D3 is the major T 3 and T 4 inactivating enzyme, catalyzing inner ring deiodination [38, 39] .
D1 was the first selenocysteine deiodinase to be discovered. It is a transmembrane protein, but its specific location on the plasma membrane or in the endoplasmic reticulum is still controversial [40] . In any case, D1 brings a limited contribution to the intracellular levels of T 3 when compared to D2 [41, 42] , possibly due to the fact that D2 has a 1000-fold lower Km for T 4 than D1, although TH sulfatation facilitates deiodination by D1 [43, 44] .
D1 expression is predominant in liver and kidneys; however, low levels have also been identified in the heart, spleen and lungs [37] . Using RT-PCR, Yonemoto et al. [45] found that D1 mRNA is expressed exclusively in cardiomyocytes, but not in cardiac fibroblasts. In cultured rat myocardial cells, D1 mRNA levels and activity were regulated by both T 3 and angiotensin II [45, 46] . T 3 upregulates D1 gene transcription through a TR-mediated mechanism, while angiotensin II produced the same effects through a mechanism possibly involving voltage-sensitive Ca 2? channel and protein kinase C. D2 is an obligate outer ring selenodeiodinase that is therefore involved in the activation of T 4 to T 3 and in the conversion of rT 3 to T 2 [38] . D2 is located in the endoplasmic reticulum where it is an integral membrane protein with the catalytic component in the cytosol [47] . D2 has been identified in several tissues. With regard to cardiac expression, there are important differences between humans and rodents. Human heart expresses high levels of D2 mRNA, whereas only low levels are present in rodent hearts [48] , and D2 overexpression in mouse myocardium leads to a mild chronic thyrotoxicosis [49] . The mechanism underlying this difference has been clarified by Dentice et al. [50] . They demonstrated that human D2 expression requires the interaction between the transcription factors Nkx-2.5 and GATA-4 and a binding site in the dio2 gene. In rat heart, however, the corresponding binding site is lacking, accounting for the low D2 mRNA levels. This observation suggests that extrapolations from rodent models to human physiology and pathophysiology should be considered with caution.
D2 is subjected to regulation by T 3 ; indeed, in rodents, T 3 administration decreased D2 mRNA levels, while methimazole-induced hypothyroidism was associated with increased D2 activity [51] . D2 expression is lower in atria than in ventricles, but the functional implications of this difference have not been explored yet.
D3 causes inner ring deiodination and converts THs into their biologically inactive counterparts [52] . It metabolizes T 4 , T 3 and T 2 , while the corresponding sulfated iodothyronines do not represent substrates for this enzyme [52, 53] . D3 is mainly expressed in embryonic and fetal tissues where its expression is strictly regulated in a tissueand time-specific pattern, suggesting that exposure of tissues to the correct TH levels plays a major role in cellular proliferation and differentiation. It has been identified also in adult tissues, but its reactivation seems to be correlated with pathological conditions, such as cancer, chronic inflammation and critical illness [39] . In the heart, increased D3 expression and activity has been associated with ventricle hypertrophy and myocardial infarction [54, 55] , as detailed below.
Active metabolites
As discussed above, T 4 deiodination yields either T 3 or rT 3 . Since both T 3 and rT 3 are still substrates for deiodinases, diiodothyronines can also be produced, namely 3,5-diiodothyronine (T 2 ), 3,3 0 -diiodothyronine and 3
T 2 has been detected in human blood by immunological methods (reviewed in ref [56] ), and recently, a novel chemiluminescence-linked immunoassay has been developed [57] . Average T 2 concentrations were close to 0.2 nM, although in about one-third of patients T 2 levels were below the detection limit of the assay. On the basis of these findings, it is likely that T 2 is also present in tissues, but so far it has not been possible to detect endogenous T 2 in heart. However, administration of exogenous T 2 has produced significant functional effects on energy metabolism, as discussed below. 3,3
0 -T2 has also been detected both by radioimmunoassay [58] and by mass spectrometry coupled to HPLC [59, 60] , and its serum concentration was in the picomolar range.
Besides deiodination, the classical pathway of TH catabolism/inactivation is thought to involve deamination (through transamination or direct oxidation) followed by decarboxylation, yielding thyroacetic acid derivatives that can undergo further deiodination steps. In the absence of deamination, decarboxylation would produce primary amines named thyronamines. In 2004, Scanlan et al. [61] observed that a specific thyronamine, 3-iodothyronamine (T 1 AM), was present in mouse brain homogenate. T 1 AM was found to interact with a specific G protein-coupled receptor (now known as trace amine-associated receptor 1, or TAAR1) and to produce functional effects, and so it was considered as a novel chemical messenger. This hypothesis has been confirmed in subsequent investigations, and the picture has grown more complex [6] : Besides TAAR1, T 1 AM may interact with other TAAR subtypes, with adrenergic receptors and with monoamine transporters; its functional effects are now known to include stimulation of lipid vs carbohydrate catabolism, neurological responses and several cardiac actions, which will be discussed below.
After the original detection in brain, T 1 AM has been identified in many rodent tissues, including the heart, through assays based on HPLC coupled to tandem mass spectrometry. In cardiac homogenates, T 1 AM concentration averaged a few pmoles per gram of tissue and was on the same order as tissue T 3 and T 4 [4] . T 1 AM biosynthetic pathway must still be clarified. Although it is usually believed that the enzyme aromatic amino acid decarboxylase can decarboxylate THs and their derivatives, this hypothesis was not confirmed in a recent investigation [62] . In a rat gut preparation, T 1 AM has been obtained after administration of exogenous T 4 , through a pathway involving deiodination to T 2 , decarboxylation to T 2 AM by ornithine decarboxylase and further deiodination to T 1 AM [63] . It is still unclear whether a similar pathway may exist in other tissues and whether cardiac T 1 AM is produced in situ or is obtained from the circulation. As a matter of fact, both H9c2 cardiomyocytes and isolated rat hearts have been shown to accumulate exogenous T 1 AM, and at the steady state cellular concentration exceeded extracellular concentration by over tenfold. The mechanism of T 1 AM uptake has not been ascertained, but it appears to be Na ? -driven [4] . Cellular accumulation might reflect the existence of membrane or intracellular binding sites. While TAAR1 is expressed in heart [64] , its density and/or the presence of additional cardiac receptors have not been determined so far.
Functional effects Genomic effects of TH
Our understanding of TH mechanisms of action has evolved in the last decades; indeed, the picture that, at the beginning, only included genomic regulation has now been broadened to include non-transcriptional actions mediated by TRs, as well as non-transcriptional and transcriptional effects mediated by other receptors.
TRs have been cloned for the first time in 1986 [65, 66] . They belong to a larger family of intracellular receptors that counts over 50 members and also includes the receptors for steroid hormones, retinoic acid, vitamin D and peroxisomal proliferators [67] . The core common structural characteristic of these receptors is represented by a central DNA-binding domain that contains two zinc fingers and by a carboxyl-terminal ligand-binding domain. TRa and b are encoded by two genes, TR A on chromosome 17 and TR B on chromosome 3, respectively. Through alternative splicing, an array of various forms of TR proteins is produced, of which only TRa1, b1, b2 and b3 are functional [68] . TRs are expressed in all tissues with a different and finely regulated pattern. With regard to the myocardium, TRa1 is predominant and is expressed alongside with TRb1 and TRb2. Indeed, in rats TRa1 covers 40 % of T 3 heart-binding capacity and, in mice, TRa mRNA represents 70 % of TR transcripts [69] [70] [71] .
TRs are transcription factors that produce their effects on gene regulation through the interaction with specific coactivators, corepressors and DNA sequences, the socalled TH response elements (TREs) that are located in the regulatory regions of a wide variety of target genes and comprise two or more receptor-binding half-sites arranged as direct, inverted or palindromic repeats [72] [73] [74] . Depending on the nature of TREs (positively or negatively regulated TREs), the hormonal status and the cellular environment, TR can repress or enhance gene transcription [72] . In the absence of T 3 , TR binds positively regulated TREs and represses their transcription through the interaction with a corepressor complex [75, 76] . On the contrary, when interacting with negatively regulated TREs, TR induces constitutive gene expression of the involved gene. T 3 binding to TR induces major conformational changes in the ligand-binding domain. In turn this produces the subsequent release of the corepressor and the recruitment of an array of coactivators that induce, in genes containing positively regulated TREs, gene transcription. While the complex of specific steps in this process and the variety of coactivators and repressors have been extensively determined [77] , the specific mechanisms involved in T 3 induction of gene repression in negatively regulated TREscontaining genes have not been fully elucidated.
In the myocardium, TH regulation concerns many genes (Table 1) , including those encoding for myofibril, sarcoplasmic reticulum and sarcolemma proteins.
With regard to the first group, TH is involved in a fine regulation of myosin heavy chain (MHC) isoenzyme predominance. The combination of two MHCs and four light chains represents the structure of myosin holoenzyme. Skeletal and cardiac muscles have a distinct pattern of expression, with the heart expressing three isoforms: V1, V2 and V3. V1 is the most efficient isoenzyme in terms of contraction speed, and it is composed of two MHCa [78] . Whereas V3, which is composed of two MHCb, and V2, which is formed by a heavy chain heterodimer of a and b, are less efficient than V1. T 3 administration has been demonstrated to increase the levels of MHCa while it decreases those of MHCb mRNA [79] . This shift in MHC expression is associated with an increased maximal velocity of shortening in isolated ventricular muscle [80] . In addition, thyroid status regulates MHC conversion from embryonic to adult isoforms during heart development. Indeed, this shift is delayed by hypothyroidism while it is accelerated by hyperthyroidism [81, 82] .
Troponin (Tn) expression is also under the control of TH. Troponin is a complex of three proteins (TnI, TnC, TnT), located on the thin filament and mediating the interactions with the thick filament. TnI has two main isoforms, known as slow skeletal TnI (ssTnI), and cardiac TnI (cTnI), whose cardiac expression is strictly regulated during development. Indeed, ssTnI is expressed during embryonic life, while cTnI is expressed in the heart from embryonic day 10 and represents the predominant TnI isoform in adult hearts. Conditions of altered TH availability influence the time course of the switching from ssTnI to cTnI. Indeed, isoform switching is delayed in hypothyroidism [83] , while it is anticipated in hyperthyroidism [84] .
TH has also been implicated in the transcriptional regulation of sarcoplasmic reticulum Ca 2? -ATPase (SERCA) that plays a pivotal role in the control of intracytoplasmic Ca 2? levels, which in turn influence both cardiac diastolic and systolic function. SERCA represents a family of three transmembrane enzymes located at the level of sarcoplasmic reticulum (SR); SERCA1 is expressed only in fast twitch skeletal muscles, SERCA2 has been found in both slow twitch skeletal muscles and myocardium, while SERCA3 is expressed in a variety of muscular and non-muscular cells. These enzymes are finely regulated by phospholamban, another transmembrane protein that inhibits SERCA function and blocks SR Ca 2? uptake. This inhibition is removed by phospholamban phosphorylation, which is induced by beta adrenergic stimulation and other transduction pathways leading to cAMP production.
The genes encoding for SERCA2 and phospholamban contain TREs and are subject to TH transcriptional regulation; indeed, T 3 and T 4 induce an increase in SERCA2 mRNA levels while reducing phospholamban mRNA levels [85] [86] [87] [88] . In addition, T 3 also affects phospholamban phosphorylation, with a time course that suggests the presence of non-genomic mechanisms [89] . These effects accelerate SR calcium uptake improving cardiomyocyte relaxation and overall cardiac diastolic function [90] . They also increase the total calcium load of the SR. Since more calcium is available for release upon sarcolemmal depolarization, the calcium transient is increased and systolic function is also enhanced. The latter effect may be potentiated by TH induction of an increased number of SR calcium channels/ryanodine receptors [91] .
Results regarding TH regulation of sarcoplasmic Na/Ca exchanger (NCX-1) gene expression are still controversial. Hojo et al. [92] demonstrated that T 3 increases both NCX-1 mRNA and protein content; however, a later report suggested that TH negatively regulates the expression of this exchanger [93] .
With regard to the third group, TH modulates the expression of b-adrenergic receptors and enzymes involved in the regulation of ion fluxes through the membrane.
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The similarities of TH cardiovascular effects to those produced by sympathoadrenal stimulation suggested the possibility that TH could act modulating the number and/or the sensitivity of cardiovascular adrenergic receptors. However, no clear-cut evidence has been obtained up to now. Indeed, several studies demonstrated that in isolated hearts or cultured cardiomyocytes, T 3 administration significantly increased the levels of beta 1 adrenergic receptor mRNA and the sensitivity to adrenergic stimulation [94, 95] . However, in vivo studies have failed to confirm these results [96] .
Moreover, T 3 affects Na/K ATPase expression, inducing an increase in a2 and b1 subunit mRNA in rat neonatal cardiomyocytes [97, 98] . T 3 also increases the ventricular expression of two voltage-gated potassium channel isoforms (Kv4.2 and Kv4.3), mediating the Ca 2? -independent transient outward current (I t ) [99] .
Interestingly, TH downregulates TRa1 expression [100] , and this effect plays a role in the progression of postischemic heart failure.
Non-genomic effects of TH
As already mentioned in the previous section, the effect of TH relies on two principal mechanisms, genomic and non-genomic ones, that can be differentiated on the basis of their time course and of the sensitivity to transcription and translation inhibitors. TH genomic actions require de novo protein synthesis and are, therefore, inhibited by compounds that interfere with translation and transcription. They are typically identifiable only after a time lapse of at least 1 h, whereas non-genomic actions are likely to occur in a time frame of seconds or minutes.
TH rapid effects appear to be initiated at specific binding sites located at the plasma membrane but also in the cytoplasm and intracellular organelles. A putative extranuclear binding site is the heteromeric integrin aVb3 [82] , a structural protein of the plasma membrane. TH interaction with integrin aVb3 can produce effects at the extracellular level, e.g., through the modulation of growth factor receptors [101] . Intracellular effects can also occur, either through translocation of proteins from the cytoplasm to the nucleus, or by activation of specific kinases involved in genomic regulation, namely Akt or mitogen-activated protein kinases (MAPKs), particularly extracellular regulated kinase 1/2 (ERK1/2) [102] [103] [104] [105] [106] .
Other putative binding sites are represented by cytosolic TRs and specific TR isoforms. As an example, cytosolic TRa1 is involved in the maintenance of the actin cytoskeleton [83] , while p30TRa1 isoform present at the plasma membrane might be involved in the regulation of the proliferation of non-malignant cells via the activation of MAPK and Akt pathways [107] .
Most non-genomic actions produced in the heart by THs are attributable to their ability to modulate ion transporters and ion channels. In rabbit myocardium, the administration of 10 -10 M T 3 and T 4 increased SERCA activity with a calmodulinmediated mechanism [108] . However, the non-genomic effects of TH on Ca 2? intracellular levels are still controversial. In particular, Lomax et al. [109] demonstrated that T 3 application (10 -9 -10 -7 M) increased intracellular Ca 2? concentration in rat ventricular myocytes, whereas Zinman et al. [110] proved the contrary in newborn rat cardiocytes.
Modulation of other ionic currents might also contribute to regulate intracellular Ca 2? content. Indeed, Huang et al. [111] demonstrated that the acute exposure of atrial cardiomyocytes to T 3 induces an increase in I Na that, in turns, activates Na ? -Ca 2? exchange and ultimately leads to an increase in intracellular Ca 2? . The effects of TH on I Na had already been described in cultured rat myocytes, where acute exposure to 10 nM T 3 slowed the inactivation of I Na [111, 112] . Other reports also identified an increased I Na after acute exposure to T 3 , but this effect was attributed to an increase in burst activity [113] . It is still unclear whether TH interacts directly with the specific ion channels or the final effect is mediated by the activation of specific intracellular pathways.
Moreover, it has been demonstrated that TH modulates Na
? exchanger in L-6 myoblasts through an extranuclear mechanism and regulates Na 
/K
? ATPase by a nongenomic action [114] . Reciprocal regulation of cardiac Na ? / K ? ATPase and Na ? /H ? exchanger has been hypothesized, but needs further evaluation [115] . TH stimulates inward rectifying K ? currents (I KI ). Indeed, in guinea pig ventricle myocytes, the acute administration of T 3 at a concentration ranging from 1 nM to 1 lM increased I KI by reducing the interbust interval [116] with the result of shortening action potential duration.
An important question is whether non-genomic effects play a significant physiological or pathophysiological role in vivo in humans. The first evidence that non-genomic actions of TH were identifiable in humans came from the work of Schmidt et al. [117] , who demonstrated that the administration of 100 lg of T 3 to healthy euthyroid male volunteers increased cardiac output and reduced systemic vascular resistance within a time frame reflecting non-genomic action.
Even though a fixed distinction between non-genomic and genomic actions of TH in the heart has been used to simplify the description of TH mode of action, it has to be underlined that the two pathways might share common targets, producing the overall effects in cardiovascular diseases that will be considered and discussed in the next sections.
Cardiac effects of T 2
Administration of exogenous T 2 has been reported to modulate energy metabolism. Rats subjected to high fat diet, and treated with T 2 at the dosage of 0.25 lg/g body weight intraperitoneally for 1 month, showed a significant reduction of body weight, liver fatty acid oxidation rate, and serum triglycerides and cholesterol [118] . Hepatic fatty acid accumulation was also reduced [119] . A reduction in body mass was confirmed in Wistar rats fed with a normal diet, which were treated with 0.25-0.75 lg/g T 2 by subcutaneous injection for 90 days [120] . Parenteral administration was required to elicit this response, since no effect was observed when similar doses were administered per os [121] . It is likely that T 2 bioavailability is reduced after oral administration, but this hypothesis has not been directly tested.
The metabolic response to T 2 has been attributed to the stimulation of mitochondrial fatty acid oxidation [122] [123] [124] [125] , possibly due to mitochondrial translocation of the fatty acid transporter FAT/CD36, which was observed in skeletal muscle mitochondria [126] . Direct interference with respiratory chain enzymes, particularly cytochrome oxidase, has also been suggested (reviewed in Refs. [56] and [127] ), and partial mitochondrial uncoupling might occur [125] , but no specific molecular target has been identified so far. While the emphasis has usually been placed on non-genomic actions, transcriptional effects have also been described, particularly increased expression of the genes coding for the alpha and beta subunits of the ATP synthase [128] .
In the investigation by Lanni et al. [118] , chronic T 2 administration (0.25 lg/g) did not produce significant changes in serum FT 3 , FT 4 and TSH, although a nonsignificant 20 % decrease in FT 4 was reported. So it was claimed that no alteration of the hypothalamus-pituitarythyroid axis was produced. Consistently, no evidence of systemic thyrotoxicosis was observed, and the heart rate was unchanged. On the other hand, according to Padron et al. [120] , treatment with 0.25-0.75 lg/g T 2 produced a dose-dependent decrease in total serum T 3 and T 4 . Serum TSH was unchanged in the 0.25 lg/g group and slightly reduced in the groups receiving higher dosages. The heart weight was unchanged, but the ratio of heart weight to body weight was significantly increased at the highest dosage. Recently, Jonas et al. [129] reported that T 2 treatment was associated with significant suppression of the hypothalamus-pituitary-thyroid axis, significant cardiac hypertrophy and changes in the pattern of gene expression similar to those induced by T 3 . It was concluded that T 2 produced thyromimetic effects. However, the dose-response relationship was at variance with the previous reports, since the responses described above were observed after 14 days of treatment with 2.5 lg/g T 2 , i.e., at a dosage about one order of magnitude higher than previously used. At the most common dosage of 0.25 lg/g, T 2 produced only minor effects, namely no change in fat mass, no change in cardiac effects and a decrease in serum T 4 but not in serum T 3 .
The concentration issue is critical to evaluate the potential physiological or pathophysiological relevance of endogenous T 2 . Initial assays with immunological methods provided estimated serum concentrations on the order of 10-20 pmol/l in humans [56] , while the CLIA method recently developed by Lemphul et al. [57] yielded average values on the order of 200 pmol/l that was close to the detection limit of the assay. Unfortunately, serum T2 could not be determined in most animal studies, except for the investigation by Jonas et al. [129] , in which treatment with 0.25 or 2.5 lg/g exogenous T 2 increased serum T 2 by 25-fold and 120-fold over the baseline, respectively. Similar relative changes were also reported for liver T 2 accumulation.
There is a single clinical investigation in which T 2 was administered to two human volunteers at a very low dosage (300 lg/day), and interestingly after 28 days body weight was decreased and resting metabolic rate was increased in both patients [130] , with no changes in cardiac function.
On the whole, T 2 appears to produce significant effects on fatty acid metabolism and on mitochondrial function, although their physiological relevance remains to be determined, and the development of more accurate assays is necessary to solve the question. Specific cardiac effects have not been described so far, but chronic high dose T 2 administration might lead to myocardial hypertrophy. It is also unclear whether the response to T 2 is mediated by specific receptors, which have not been identified yet, or whether it is related to thyromimetic effects. The latter are certainly possible at high dosages, because T 2 has a low affinity for TRb [131, 132] . Since recent evidence suggests that T 2 might be a precursor of T 1 AM, an intriguing hypothesis is that some effects of exogenous T 2 might actually be due to increased T 1 AM production.
Cardiac effects of T 1 AM
In the isolated rat heart, administration of exogenous T 1 AM produced within a few seconds a significant negative inotropic effect, as shown by reduced aortic flow, cardiac output and developed pressure [61] . The heart rate was also decreased, although the negative inotropic and chronotropic effect could be dissociated, and the former occurred at lower concentrations. Dose-response curved yielded IC 50 's of 20 and 40 lM for the decrease in cardiac output and heart rate, respectively [64, 133] . These effects were reversible after washing out T 1 AM and could be counteracted by positive inotropic and chronotropic agents, such as isoproterenol. Substantial bradycardia was also demonstrated in vivo, in mice treated with 50 mg/kg T 1 AM i.p. [61] .
Cell culture experiments performed with H9c2 cardiomyocytes showed that the negative chronotropic effect was due to a decrease in the calcium transient, which was probably accounted for by increased diastolic calcium leak from the SR, leading to a reduction in the SR calcium pool [134] . In fact, in SR vesicles loaded in vitro with 45 Ca, the kinetics of calcium-induced calcium release was normal, but passive calcium efflux was significantly increased under conditions promoting closure of the SR calcium release channel. Electrophysiological experiments did not reveal any significant effect on the L-type calcium channel, while a delayed rectifier potassium channel was inhibited [134] . The latter effect, if confirmed also in the pacemaker cells of the sinus node, might contribute to the observed negative chronotropic response.
TAAR1 is expressed in heart [64] , but it is unclear whether it is involved in the observed functional effects, since the potency of other trace amines was not consistent with their affinity for TAAR1 [133] . Other TAARs are also expressed in rat heart, particularly TAAR8, but it remains to be determined whether they are activated by T 1 AM and can modulate contractile function. Interestingly, recent investigations suggest that T 1 AM might be an inverse agonist at TAAR5 [135] and that it can also interact with adrenergic receptors, particularly a 2A receptors [136] .
The negative inotropic response was accentuated by genistein, a tyrosine kinase inhibitor, and counteracted by vanadate, a tyrosine phosphatase inhibitor. In addition, Western blot experiments with anti-phosphotyrosine antibodies showed reduced tyrosine phosphorylation of as-yet unidentified proteins in the microsomal and cytosolic fraction [64] . Therefore, it has been suggested that the transduction pathway activated by T 1 AM may reduce the phosphorylation of tyrosine residues on protein targets regulating ionic homeostasis.
T 1 AM has also been tested in a model of ischemiareperfusion injury, represented by the isolated perfused rat subjected to 30 min of ischemia and 120 min of retrograde reperfusion. A significant reduction in infarct size was observed, but the dose-response curve was bell-shaped, since effective concentrations ranged from 125 nM to 12.5 lM, while higher doses were not protective [137] . So cardioprotection was dissociated from the negative inotropic effect and was actually observed in the absence of any change in pre-ischemic contractility or heart rate. A different transduction pathway was probably activated, since protection was abolished by chelerythrine, a protein kinase inhibitor, which did not affect the inotropic and chronotropic effects of T 1 AM [64] . The putative mitochondrial K ATP channel glybenclamide also antagonized the response to T 1 AM. It was therefore speculated that T 1 AM might activate the transduction pathways involved in ischemic preconditioning, which are known to involve protein kinase C and mitochondrial effectors [137] . Interestingly, mitochondrial effects of T 1 AM have also been reported, since in isolated mitochondria T 1 AM concentrations in the nanomolar range affected ATP synthase activity, oxygen consumption and free radical production [138, 139] .
A crucial question is the potential physiological or pathophysiological relevance of endogenous cardiac T 1 AM. So far this issue has been addressed only by comparing the effective doses of exogenous T 1 AM with endogenous T 1 AM levels. As discussed above, cardiac T 1 AM concentration lies in the nanomolar range (i.e., pmol/g), and so it is about three orders of magnitude lower than the IC 50 for the negative inotropic effect produced by exogenous T 1 AM. Therefore, it is hard to believe that endogenous T 1 AM may modulate contractile function, while it might affect the susceptibility to ischemic injury. However, it must be acknowledged that we still do not know the extent of T 1 AM compartmentation and the rate of its metabolic clearance [4] . Therefore, it is difficult to compare the endogenous concentrations occurring at receptor level under physiological conditions with those achieved when exogenous T 1 AM is administered in experimental models. Understanding the physiological role of cardiac T 1 AM will eventually require a more direct approach, which could be made possible by the development of specific receptor antagonists and appropriate transgenic models. This will in turn depend on further insight in T 1 AM biosynthesis, catabolism and signaling.
With regard to TAM metabolism, the heart has been shown to oxidize T 1 AM to 3-iodothyroacetic acid [4] . In other tissues, deiodination to thyronamine (T 0 AM), Nacetylation and conjugation to sulfate and glucuronate have also been reported [140] . Interestingly, T 0 AM shares the negative inotropic and chronotropic properties of T 1 AM, although it is about tenfold less potent [133] , while 3-iodothyroacetic acid does not produce significant functional effects [141] . The potential cardiac effects of T 1 AM derivatives represent therefore another interesting research field.
Pathophysiological implications
The heart in hyperthyroidism
In hyperthyroidism, TH effects on the heart are amplified, eventually leading to a hyperdynamic cardiocirculatory state. In hyperthyroid patients, cardiac output is higher than in normal subjects, as the result of different factors ( Fig. 1) : increased resting heart rate, increased ejection fraction, increased blood volume and decreased systemic vascular resistance. It is still controversial if the high cardiac output condition is mainly due to the direct actions of T 3 on cardiomyocytes (myocardial hypothesis) or to indirect hemodynamic changes (vasculature hypothesis), or maybe to a balanced interaction between these two mechanisms [142] . Early in 1986, Klein et al. tried to separate the two different mechanisms using an animal model in which a heterotopically transplanted heart coexisted with the recipient's in situ heart. In this model, TH administration caused a larger increase in weight and protein content in the in situ working heart than in the nonworking heart [143] , supporting the concept that cardiac work and hemodynamic changes play a major role in the cardiac effects of hyperthyroidism.
The direct effects of high levels of TH on cardiomyocytes are consistent with the physiological responses described above, namely increased transcription of the genes for MHC a and SERCA2, while phospholamban gene expression is reduced and phospholamban phosphorylation is decreased. Specific effects on the electrical activity of specialized myocytes in the sinus node have also been reported [144] . In rats, TH administration increased the expression of hyperpolarization-activated cyclic nucleotide-gated channel gene (HCN2) [145] that is involved in pacemaker activity. Other ion channel proteins in the sinus node of the left atrium were also modulated by either genomic or non-genomic mechanisms, namely SR calcium channel, sodium/calcium exchanger protein and sarcolemmal L-and T-type calcium channels [144] . Elevated levels of TH can reduce peripheral vascular resistance, through either direct or indirect actions. Indeed, T 3 directly reduces the expression of angiotensin II type 1 receptor on peripheral vasculature and the contractile response to angiotensin II, while it stimulates the signaling pathway leading to nitric oxide (NO) production that decreases calcium concentration and calcium sensitivity [146] . Data obtained in rat aortic rings suggest that the vasodilatory effect of TH is mediated by the endothelium [147] . However, T 3 can also act on vascular smooth muscle cell (VSMCs) in a rapid non-genomic way, causing NOdependent relaxation, through the phosphatidylinositol 3-kinase/protein kinase B (PI3K/A) pathway [148] .
The eventual functional effects include relaxation of arterial smooth muscle fibers and reduction in peripheral resistance. The latter is also supported by the increased metabolic rate that is produced in most tissues as a consequence of the metabolic effects of TH. As a result of peripheral vasodilatation, vasopressor reflex responses lead to tachycardia, while the renin-angiotensin-aldosterone system is activated, with increased sodium resorption, leading to increased preload [146] .
These mechanisms explain why increased cardiac output is the typical feature of hyperthyroidism and account for the symptoms and signs of hyperthyroidism: tachycardia, palpitation, systolic hypertension with decreased diastolic arterial pressure, increased left ventricular mass and systolic murmurs due to increased cardiac output. Sinus tachycardia is the most common arrhythmia in hyperthyroidism, but atrial fibrillation has a rather high prevalence (2-20 %), increasing with age. In the presence of preexisting coronary artery or cardiac muscle disease, angina pectoris may be triggered by the increased energy demand, while heart failure can develop as a consequence of decreased diastolic filling and impaired systolic function.
The heart in hypothyroidism
Hypothyroidism is characterized by low levels of T 3 and T 4 , with compensatory high levels of TSH (except in the case of central hypothyroidism). In general, the cardiac effect of hypothyroidism is opposite to that due to hyperthyroidism, although symptoms and signs may be milder, at least in the early phase (Fig. 1) .
When T 3 concentration is low, TH-dependent transcriptional effects are attenuated, leading to significant changes in contractile function. Delayed diastolic relaxation is a common feature in hypothyroidism, and it has been attributed to increased transcription of phospholamban that inhibits cardiomyocyte SERCA2. The relevance of this target was confirmed using transgenic mice in which the SERCA2 gene was not under TH control, since hypothyroid transgenic mice had a normal contractile phenotype [149] . In hypothyroid animals, mRNA and proteins levels of MHC b were decreased and altered myosin composition may contribute to functional abnormalities. Non-genomic actions of TH on cardiomyocytes can also be relevant in hypothyroidism, leading to modifications of sodium, calcium and potassium channels, as described above, and these effects may eventually reduce cytosolic calcium availability [90] .
The impairment of contractile function in hypothyroidism appears to be mainly mediated by thyroid hormones receptor a (TRa), since TRa knockout mice showed the typical features consisting in delayed relaxation, decreased tension development and lower heart rate, while TRb knockout mice had normal contractile function [71] .
These experimental results are consistent with the clinical findings reported in hypothyroidism, namely bradycardia, subnormal cardiac output, prolongation of the preejection period and reduction in left ventricular ejection period. On the whole, mechanical efficiency is impaired, despite a reduced myocardial oxygen demand. Myxedema can occur as a result of a long-standing undertreated hypothyroidism, and the term refers to the thickened, nonpitting edematous changes to the soft tissues of patients in a markedly hypothyroid state.
Hypertension is another feature of the hypothyroid state: Blood pressure is higher, not easily controlled by conventional therapies and reversible after reaching euthyroidism. The pathophysiological mechanisms seem to be an increase in peripheral resistance [150] and in arterial stiffness secondary to myxedema of the arterial wall [151] . Heart function may be further compromised by the development of pericardial effusion, which occurs with severe, longstanding overt hypothyroidism [152] . Moreover, in longstanding hypothyroidism left ventricular hypertrophy can develop, due to interstitial myxedema. Finally, hypercholesterolemia and hypertension cause an increased risk of atherogenesis and coronary artery disease.
Some cardiac abnormalities have been described even in subclinical hypothyroidism, particularly slow diastolic relaxation with impairment of early ventricular filling at rest and after exercise. Recently, a large cross-sectional survey of postmenopausal women [153] revealed a strong association between subclinical hypothyroidism and atherosclerotic cardiovascular disease, independent of the traditional risk factors.
In the context of subclinical hypothyroidism, it was recently argued that the crucial variable is represented by TH tissue concentration, which may be altered in spite of quite normal serum TH concentrations. Liu et al. created an animal model in which thyroidectomized rats were implanted with slow-release pellets containing T 4 , enabling the analysis of graded levels of TH function. At low T 4 dose, a dissociation was observed between serum and cardiac TH concentrations: Serum T 3 and T 4 were normalized, but cardiac T 3 and T 4 remained subnormal. Moreover, low-dose T 4 failed to prevent cardiac atrophy or restore cardiac function and arteriolar density to normal values [154] . Consistently with these data, Saba et al. [155] applied a novel liquid chromatography-tandem mass spectrometry method to the quantification of cardiac tissue THs in a rat model and confirmed that, after administration of exogenous T 3 or T 4 , similar tissue T 4 values were obtained within a relatively large range of plasma T 4 .
Occurrence of tissue hypothyroidism in heart failure
The interaction between TH and heart is bidirectional, since altered TH metabolism has been reported in patients with heart insufficiency and a normal thyroid gland. Typically, T 3 is low, despite initially normal TSH and T 4 levels. In heart failure patients, the decrease in T 3 was proportional to the severity of the disease, suggesting that a sort of ''low-T 3 syndrome'' is an independent predictor of a poor prognosis in heart failure [156] .
In general, failing cardiomyocytes show a pattern of gene expression similar to that found in hypothyroidism, with regard to key proteins such as contractile proteins, sodium-calcium exchanger and b-adrenergic receptors. Apart from changes in serum THs, the molecular mechanisms might be: (1) modulation TRs and coreceptors, (2) reduction in transporter activity and consequently of TH uptake and (3) changes in local THs metabolism (Fig. 2) .
In explanted hearts from patients undergoing transplantation, a significant decrease in TRa1 was observed, while the expression TRa2, which is unable to bind TH and is therefore considered as a suppressor of gene transcription, was increased [157] . In a mouse model of heart failure induced by ascending aortic constriction, reduced expression of TRa1 and TRb1 was also reported [158] . More recent experimental investigations have opened a new scenario, suggesting that TRa1 expression could play a role as a regulator of dedifferentiation/redifferentiation in cardiac stress, depending on the presence or absence of TH. In particular, TRa1 may trigger remodeling and reparative processes, possibly by non-genomic mechanisms involving the PI3K/Akt/mTOR (mammalian target of rapamycin) signaling pathway or the p38MAPK cascade. The latter has also been related to TRa1-specific cardiac hypertrophy. These findings have potential clinical relevance, since these molecules can be targets of new therapeutic approaches in heart failure [159] . While changes in cardiac TH transporters have not been reported in heart failure, the activity of deiodinases is another crucial issue. In particular, D3 induction appears to be involved in the progression of cardiac hypertrophy, from an adaptive to a maladaptive stage, precipitating heart failure. In a model of post-infarction heart failure in mouse, Pol et al. [160] reported increased D3 activity and a significant reduction in tissue T 3 , with normal serum T 3 . Wassen et al. created a mouse model of heart failure in which chronic pulmonary arterial hypertension was induced by a single dose of pyrrolizidine alkaloid monocrotaline: Part of these mice developed congestive heart failure (CHF) and died within 4-5 weeks. In CHF mice, the pattern of gene expression resembled hypothyroidism, plasma T 4 , FT 4 and T 3 were significantly reduced (40-60 %) with normal TSH, and there was a fivefold increase in cardiac D3 activity [55] .
These investigations suggest that the increase in D3 in heart hypertrophy and failure could lead to a local reduction in T 3 , independently from the serum levels, and contribute to a ''hypothyroid'' condition in the affected myocardium. The trigger for the increased D3 activity seems to be the mismatch of oxygen delivery and consumption in the hypertrophic cardiomyocytes, with subsequent intracellular stabilization of the transcription factor HIF1a that directly stimulates D3 gene expression [55] .
The hypothesis that the failing heart is in a ''local hypothyroid state'' arises the question whether treatment with T 3 could be beneficial. This issue is further described in this issue by Pingitore et al.
TH and the ischemic heart
Low levels of T3 are commonly observed in patients in the first hours after acute myocardial infarction (AMI) and seem to correlate with the prognosis. Independently from prompt therapies and primary percutaneous coronary intervention, T 3 levels were inversely related to recovery time and ejection fraction (EF %) [161] .
Since THs are crucial for embryonic heart development, they have been suggested to play a key role in the reactivation of fetal phenotype after myocardial injury and in damage reparation. A central role in this shift to embryonic signaling is the reexpression of TRa1, which is also involved in the progression to heart failure, as discussed above. After AMI, cardiac hypertrophy occurs as a compensatory effect: In this condition, TRa1 is redistributed from the cytosol to the nucleus, in a process regulated by ERK and mTOR signaling. In cell culture experiments, TRa1 exposure to low levels of TH induced cardiomyocytes dedifferentiation, while in the presence of adequate TH concentration differentiation was induced, possibly leading to reparation of injured myocardium. This question is extensively discusses in this issue by Cokkinos et al.
Conclusions and open questions
The heart is a major target organ of THs, and cardiac abnormalities play an important role in the phenotypes of both hyperthyroidism and hypothyroidism. The clinical features can be understood on the basis of the genomic and non-genomic actions of THs on the myocardium and blood vessels, but the recent paradigm shift in described in this review has opened new perspectives and introduced new questions (Fig. 2) .
Subtle cardiac abnormalities have been observed in subclinical hypothyroidism. Basic science investigations have provided an explanation for these observations, by showing that tissue and serum TH concentrations are not identical, because of the complexity of transmembrane TH transport and tissue metabolism. Similar considerations suggest that the failing heart may actually be hypothyroid, because tissue T 3 concentration may be reduced in spite of normal circulating THs. This possibility has been clearly demonstrated in specific experimental models of heart failure and attributed to the induction of D3 deiodinase, favoring T 4 inactivation to rT 3 over T 3 production. Changes in TRa1 expression might also contribute to the phenotype of the failing heart.
The actual occurrence of tissue hypothyroidism in human heart failure is still uncertain, and its implications are controversial. Since TH increases cardiac contractility, reduced T 3 availability might be a causal mechanism contributing to contractile failure. On the other hand, it has been argued that reduced oxygen consumption linked to tissue hypothyroidism might be a compensatory mechanism, delaying the progression of cardiac insufficiency, particularly in ischemic heart disease. The ongoing clinical trials will hopefully provide new evidence to solve this controversy.
Experimental investigations have also shown that exposure to THs is able to affect the susceptibility to ischemia and the long-term recovery after myocardial infarction. This is consistent with the role played by THs in other cases of regeneration and repair and points to another possible subject for clinical investigations.
Further complexity has been introduced by the discovery of the functional effects of TH derivatives, like T 2 and T 1 AM. While no specific cardiac effects have yet been described for T 2 , T 1 AM produces a negative chronotropic and inotropic effect in different experimental models. However, the physiological importance of these actions is uncertain, since they were observed in vitro at doses that turned out to be much higher than the endogenous levels.
Notably, T 1 AM affects ischemic injury at much lower dosages and might contribute to the modulation of cardiac function in ischemic heart disease.
Since 
